Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jun Guo, MD
CONTACT
Lu Si, MD
CONTACT
Lead
Qilu Pharmaceutical Co., Ltd.
This study is divided into two parts. The first part is the safety and tolerability observation period, mainly observing the safety and tolerability of QLF31907. The second part is mainly the efficacy observation period, further evaluating the efficacy and safety of QLF31907 in patients with advanced melanoma and urothelial carcinoma.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted